| Trial ID: | L3199 |
| Source ID: | NCT01213563
|
| Associated Drug: |
Actrapid Insulin+Gloucose
|
| Title: |
Management of Type 2 Diabetes After Gastric Bypass Surgery
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Actrapid insulin+Gloucose|DRUG: Actrapid insulin
|
| Outcome Measures: |
Primary: efficacy and safety of an intensive glycaemic protocol after bariatric surgery, insulin+Gloucose, 1 year |
|
| Sponsor/Collaborators: |
Sponsor: Imperial College London
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE
|
| Start Date: |
2009-01
|
| Completion Date: |
2010-09
|
| Results First Posted: |
|
| Last Update Posted: |
2020-08-21
|
| Locations: |
Imperial College London, Charing Cross Hospital, London, W68NA, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT01213563
|
